Kris on Oncology

• Pembrolizumab +/- Chemotherapy: Reading Between the Studies   Dr Mark Kris discusses how to read between the studies to determine optimal treatments for patients when clinical trial data are not available.
  Medscape Oncology, December 30, 2021
• Early Data Support Neoadjuvant Immunotherapy for NSCLC   A handful of studies on neoadjuvant immunotherapy for lung cancer are nearing completion, Mark Kris reports.
  Medscape Oncology, December 22, 2021
• Adjuvant Atezo in Stage II/IIIA Lung Cancer: A New Standard?   Dr Mark Kris discusses a recent trial demonstrating improved disease-free survival for patients with resected stage II to IIIA, PD-L1-positive lung cancer treated with atezolizumab following cisplatin-based chemotherapy.
  Medscape Oncology, December 01, 2021
• Tips to Reduce Treatment Downtime in Lung Cancer   Dr Mark Kris discusses waiting in the oncology setting, focusing on the importance of communication with colleagues and with patients.
  Medscape Oncology, November 29, 2021
• Treatment Tips for Challenging EGFR-Mutant Lung Cancers   Dr Mark Kris discusses challenges related to treating lung cancers with EGFR mutations.
  Medscape Oncology, November 23, 2021
• ASCO 2021 ASCO Lung Cancer Targeted Therapy Data Expands EGFR and MET   Some of the new targeted therapies work even when the mechanism is unknown, says Dr Kris.
  Medscape Oncology, July 29, 2021
• ASCO 2021 ASCO 2021: Best Lung Cancer IO Data   Pooled analysis supports chemo + immunotherapy for patients with PD-L1 1%-49%; immunosuppressants for adverse effects of immunotherapy; and AI predicts outcomes better than pathologic exam.
  Medscape Oncology, July 21, 2021
• ASCO 2021 ASCO Data Present 'Clear Roadmap' to Treat Locally Advanced NSCLC   'These studies point to the need for multimodality therapy for the patients with locally advanced NSCLC,' says Dr Mark Kris.
  Medscape Oncology, July 09, 2021
• Osimertinib: A Bright Spot at the End of a Dismal 2020   Approval of the first adjunctive treatment for patients with stage IB to IIIA lung cancer is a harbinger of targeted therapies to come, says Dr Mark Kris.
  Medscape Oncology, January 19, 2021
• Top 10 Advances in Thoracic Oncology in 2020   Dr Mark Kris details what he considers the 10 most important developments in lung cancer management from 2020.
  Medscape Oncology, January 19, 2021
• NCCN Guidelines Pave Way for Improving Lung Cancer Survival   Recently updated NCCN guidelines have Dr Mark Kris excited about the future of lung cancer treatment and survival.
  Medscape Oncology, January 07, 2021
• ESMO 2020 Osimertinib as Adjuvant Therapy in EGFR-Mutant Lung Cancer   Dr Mark Kris discusses how recent data presented at ESMO continue to support osimertinib as an important drug in the adjuvant setting for patients with completely resected EGFR-mutant lung cancer.
  Medscape Oncology, October 16, 2020
• ESMO 2020 An Important Negative Study for Post-op RT in Lung Cancer   With Lung ART results not showing benefit for postoperative radiotherapy in stage IIIA lung cancer, Dr Mark Kris says it can't be recommended as standard of care for all patients but may benefit some.
  Medscape Oncology, October 08, 2020
• Checkpoint Inhibitors: Sooner Than Later in Lung Cancer?   Checkpoint inhibitors may offer a 'unique opportunity' to improve the cure rate in lung cancer, says Dr Mark Kris.
  Medscape Oncology, September 14, 2020
• Confronting Isolation Among Cancer Patients During COVID-19   Dr Mark Kris discusses the importance of oncologists helping their patients to overcome physical and psychological isolation during these unprecedented times.
  Medscape Oncology, August 28, 2020
• Gefitinib Plus Chemo for NSCLC With EGFR Mutations   Dr Mark Kris discusses recent studies that provide evidence for a new standard of care -- gefitinib plus chemotherapy -- in patients with NSCLC and an EGFR-activating mutation.
  Medscape Oncology, July 27, 2020
• When to Add Chemo to IO in Lung Cancer? New Data From ASCO 2020   Immunotherapeutic agents are bringing our lung cancer patients closer to cure, says Mark Kris.
  Medscape Oncology, July 22, 2020
• ADAURA Trial Changes Lung Cancer Treatment in Two Important Ways   Dr Mark Kris discusses recent practice-changing abstracts in lung cancer, presented at the virtual 2020 ASCO meeting.
  Medscape Oncology, July 13, 2020
• Progress in Targeted Therapy for Lung Cancer: New Data   Dr Mark Kris explains why he is even more hopeful when it comes to targeted therapy for lung cancer after seeing several trial results presented during this year's virtual ASCO meeting.
  Medscape Oncology, June 30, 2020
• Should ADAURA Trial Results Change Practice in NSCLC?   Dr Mark Kris says yes and explains why he thinks 3-year treatment with osimertinib should become the new standard of care for patients with EGFR mutation–positive NSCLC.
  Medscape Oncology, June 30, 2020